Transneural bolsters leadership team with key R&D hire

US brain specialist Transneural Therapeutics has named industry veteran Mark Demitrack as its chief research and development officer, as the company prepares to move its lead candidate for depression and PTSD into the clinic.

The Seattle-based firm, which is focused on developing non-hallucinogenic neuroplastogens for serious brain disorders, said Mr Demitrack brings decades of clinical and scientific leadership to the role.

Chief executive Charmaine Lykins described the appointment as timely, pointing to Mr Demitrack’s history of securing multiple drug approvals. “He has a comprehensive command of all phases of drug development,” she said, highlighting plans to accelerate work on TN-001, the company’s first drug candidate.